EBF3

Summary: Chromatin association is consistent with the classified EBF transcription-factor role and direct human-cell evidence.

Reason: GO_REF:0000113 supplies a manual family-based chromatin assertion, and the current TFClass table places EBF3 within 6.1.5. PMID:28017373 independently reports tight chromatin association of wild-type human EBF3 by in situ fractionation and binding at cis-regulatory target regions in SK-N-SH cells. The inherited ISA evidence remains a classification assertion, rather than being relabeled as a direct chromatin experiment. Chromatin and the broader nuclear pool are both biologically supported.

Summary: EBF3 recognizes cis-regulatory DNA in its Pol II transcription-factor function.

Reason: The literal GO:0000978 IBD is placed at PTN000844136, and the current PTHR10747 tree places human EBF3 beneath it through a 14-node path; the target MSA sequence exactly matches the official 596-residue protein. The supporting Ebf1/Ebf2/Ebf3 and EBF4 identities and positive experimental source records are traceable. Human EBF3 target-region binding in PMID:28017373 and the COE-site reporter in PMID:28017372 agree with this ancestral activity. The reporter alone is not a purified DNA-affinity assay, and no target-lineage loss assertion or functional divergence was found.

Summary: EBF3 is a sequence-specific transcription factor acting on Pol II-transcribed genes.

Reason: The literal GO:0000981 IBD at PTN000844136 is inherited by the verified human EBF3 leaf in PTHR10747. Direct human EBF3 transcription assays include Cd79a-linked activation, a synthetic COE-site reporter, and CDKN1A promoter activation; these support the conserved Pol II TF function. Effects depend on protein dosage, mutation and cellular context, so the broad TF term appropriately does not assert uniform activation of every bound locus.

Summary: The manual TFClass assignment correctly identifies EBF3 as a Pol II DNA-binding transcription factor.

Reason: The authentic TFClass table identifies EBF3 at 6.1.5.0.3. GO_REF:0000113 describes manual evaluation of DNA-binding TF families for GO:0000981, and human EBF3 reporter and target-regulation experiments independently support that classification. Structural family membership and the functional experiments are distinguished; the ISA row does not claim that the classification resource itself performed a reporter assay.

Summary: Refine broad DNA binding to Pol II cis-regulatory region sequence-specific DNA binding.

Reason: The current InterPro matches reproduce the broad DNA-binding mappings from IPR003523, IPR032200 and IPR038173. EBF3 has the more informative cis-regulatory DNA-recognition activity represented by the independently curated GO:0000978 IBA, supported by human target-region binding and COE-site transcription experiments. GO:0000978 is a typed descendant of GO:0003677. This target-level refinement does not imply that each domain match independently establishes promoter recognition or that the original mapping was false.

Proposed replacements: RNA polymerase II cis-regulatory region sequence-specific DNA binding

Summary: Refine generic DNA-binding TF activity to the Pol II-specific activity.

Reason: The current IPR038006 match and its GO:0003700 mapping are genuine. Human EBF3 regulates Cd79a-linked and CDKN1A transcription and activates a COE-site reporter; together with the manually curated family and PAINT evidence this supports GO:0000981. The current typed ontology places GO:0000981 below GO:0003700. The refinement describes the whole protein and does not claim that the isolated IPT-domain match was independently assayed as a complete transcription factor.

Proposed replacements: DNA-binding transcription factor activity, RNA polymerase II-specific

Summary: The inherited nuclear localization is supported by human EBF3 and conserved family evidence.

Reason: The literal nuclear IBD at PTN000844136 includes human EBF3 together with mouse Ebf1 and worm unc-3 as experimentally grounded descendant sources. Human EBF3 lies below that node, and PMID:28017373 independently reports nuclear wild-type protein in transfected human cells. The target appearing among the IBD sources is expected and is not circular. Retain nucleus as a nonexclusive compartment; mutant redistribution and chromatin association do not invalidate this broader pool.

Summary: Wild-type human EBF3 is nuclear in the reported human-cell localization assay.

Reason: PMID:28017373 reports nuclear FLAG-tagged wild-type EBF3 in HEK293T cells, whereas several disease-associated mutants distribute between nucleus and cytoplasm. The wild-type observation supports nucleus; it is not a universal claim of exclusive nuclear residence in every cell type or condition. The separate in situ fractionation and SK-N-SH target-binding experiments provide chromatin context without replacing the resolution of this localization assertion.

Summary: The UniProt subcellular-location mapping to nucleus is biologically supported.

Reason: The current official SL-0191 record maps directly to GO:0005634, and GO_REF:0000044 describes this controlled-vocabulary mapping. Human EBF3 localization in PMID:28017373 independently supports the nuclear assignment. Retain the nonexclusive nuclear compartment; the mapping is not used to infer a narrower nucleoplasmic pool or universal absence from cytoplasm.

Summary: Refine general transcription regulation to regulation of transcription by RNA polymerase II.

Reason: IPR003523 and IPR038006 genuinely map to broad transcription regulation. Assays of human EBF3 using Cd79a-linked, COE-site and CDKN1A reporters, together with the existing GO:0006357 IBA, identify the Pol II context. GO:0006357 is a typed descendant of GO:0006355. Retaining a direction-neutral regulatory term at this family-mapping level accommodates locus-, dose- and mutation-dependent effects without manufacturing a universal activation claim.

Proposed replacements: regulation of transcription by RNA polymerase II

Summary: Regulation of Pol II transcription is a conserved EBF3 function supported in human cells.

Reason: The literal GO:0006357 IBD at PTN000844136 contains the recorded vertebrate and invertebrate descendant sources, and the exact human EBF3 leaf inherits it. Human EBF3 transcriptional activation and target-regulation experiments support this process directly. The positive responses in selected assays and reduced response at very high expression do not require changing the conserved direction-neutral regulatory assertion or adding a separate negative-regulation annotation.

Summary: Refine EBF3-dependent transcriptional activation to positive regulation of Pol II transcription.

Reason: PMID:28017370 expressed human EBF3 in μM2.21 plasmacytoma cells and measured surface IgM as the Cd79a-linked transcriptional readout. Wild-type protein activated the response at low and intermediate expression, while high expression reduced it; R163P was inactive across the tested expression gates. P177L and K193N showed residual activation at high dosage, but the paper describes near-wild-type activity specifically for P177L. K193N's residual high-dose response does not establish normal activity and is compatible with the significant loss of transcriptional activation recorded in UniProt Q9H4W6 VAR_078041. Figure 3A–B and its adjacent Results resolve the dose dependence; the abstract's reduced-activity statement does not itself supply those dose-specific details. GO:0045944 preserves the directly measured positive effect on a Pol II-transcribed target without implying purified DNA affinity or a native human neuronal program.

Proposed replacements: positive regulation of transcription by RNA polymerase II

Summary: Refine the human COE-site reporter activation to positive regulation of Pol II transcription.

Reason: PMID:28017372 used untagged human EBF3 in HEK293 cells with a six-COE-site NanoLuc reporter, firefly transfection control and empty-vector/no-transfection/COE-deletion controls. Wild-type protein activated the reporter, R163L retained partial activity and R163Q was severely impaired. The deposited templates HQ258299 and BC130479.1 translate exactly to the current 551-residue Short product, without requiring any edit to the gene-level source assertion. This supports GO:0045944; the separate HA-tagged fly rescue is conserved biological corroboration, not the human transcription assay or direct purified DNA binding.

Proposed replacements: positive regulation of transcription by RNA polymerase II

Summary: Refine CDKN1A promoter activation to positive regulation of Pol II transcription.

Reason: PMID:28017373 reports activation of a pGL2-p21/CDKN1A luciferase reporter by wild-type human EBF3 in HEK293T cells, with reduced or absent activation by several tested disease variants. The separate SK-N-SH RNA and chromatin-binding experiments provide target-regulatory context; P177L retains some binding and regulation, and dominant-negative effects vary by variant. GO:0045944 captures the assayed Pol II promoter activation more precisely than GO:0045893 without claiming that all EBF3 targets are activated or every disease allele has the same mechanism.

Proposed replacements: positive regulation of transcription by RNA polymerase II